Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 10

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 10
---
atus Merger by filing a certificate of merger with the Secretary of State of the State of Delaware in accordance with the applicable provisions of the Delaware Limited Liability Company Act, with each of the Mergers being consummated and effective simultaneously as of April 30, 2025.

In connection with the Business Combination, the Company filed an amended and restated certificate of incorporation, which, among other things, changed the Company’s name to “Liminatus Pharma, Inc.”

On the Closing Date, the Business Combination, among other transactions contemplated by the Business Combination Agreement, was completed (the “Closing”).

Effect of the Business Combination on Existing Iris Equity

Pursuant to the Business Combination Agreement:

<div align='center'>7</div>

| (i) | immediately prior to the effective time of the Mergers, every issued and outstanding Iris Unit automatically separated into its constituent parts and the holder thereof were deemed to hold one share of Iris Class A Common Stock and one-fourth of one whole redeemable warrant that was included as part of each Iris Unit; |

| (ii) | at the Effective Time, each issued and outstanding Iris Class A Share converted automatically into one share of ParentCo Common Stock, following which all Iris Class A Shares were automatically cancelled and ceased to exist and be outstanding; |

| (iii) | at the Effective Time, each issued and outstanding Public Warrant, in accordance with the terms of the Warrant Agreement, immediately and automatically converted into the right to purchase shares of ParentCo Common Stock on the same terms and conditions as are set forth in the Warrant Agreement; |

| (iv) | at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase one Iris Class A Share at $11.50 per share, except those issued to Cantor Fitzgerald & Co., were forfeited; and |

| (v) | at the Effective Time and in accordance with the Warrant Agreement, each Private Placement Warrant issued to Cantor immediately and automatically converted into the right to purchase shares of ParentCo Common Stock on the same terms and conditions as are set forth in the Warrant Agreement. |

At the Effective Time, each share of common stock of SPAC Merger Sub outstanding immediately prior to the Effective Time converted into an equal number of shares of common stock of Iris each of which is held by ParentCo, with